Since Tlx-amplified NSCs in combination with other genetic alteration contribute to tumorigenesis in the nervous system, Tlx may become a good diagnostic marker and therapeutic target for patients with malignant gliomas. This evidence concerns the gene NR2E1 and malignant glioma.